Samjin Pharmaceutical Co Ltd
KRX:005500
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (10.4), the stock would be worth ₩19 750.01 (4% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 10 | ₩19 060 |
0%
|
| 3-Year Average | 10.4 | ₩19 750.01 |
+4%
|
| 5-Year Average | 12.6 | ₩23 935.46 |
+26%
|
| Industry Average | 15.3 | ₩29 176.89 |
+53%
|
| Country Average | 9 | ₩17 117.51 |
-10%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
S
|
Samjin Pharmaceutical Co Ltd
KRX:005500
|
241.3B KRW | 10 | 10 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 49.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 22.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 19.6 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 14.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 16.5 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.9 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 12.9 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 8.3 | 16.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 4.2 |
| Median | 9 |
| 70th Percentile | 16.6 |
| Max | 2 215 132.4 |
Other Multiples
Samjin Pharmaceutical Co Ltd
Glance View
Samjin Pharmaceutical Co., Ltd. engages in the manufacture, distribution, and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 755 full-time employees. The Company’s products include antipyretics, analgesics, antiphlogistic agents, osteoarthritis agents, osteopathic agents, antihistaminic agents, circulatory system drugs, gastrointestinal agents, osteoporosis treatments, hepatic disease agents, respiratory agents, antibiotics agents, detoxifying agents, antifungal agents, antineoplastic agents and others. Its products are provided in the forms of tablets, injections, capsules and others. The company distributes its products to the hospitals and drugstores. The firm supplies its products within domestic market and to overseas markets.
